Magnetic Brain Stimulation to Study Walking in Multiple Sclerosis
Tests repeated magnetic brain stimulation on walking in adults with multiple sclerosis and leg stiffness.
Plain-language title generated from the registry record
Registry title: Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
Key facts
- Where
- Gatineau, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07159789, who can take part
Where in Canada
- Clinique Neuro-OutaouaisGatineau, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Clinique Neuro-Outaouais
- Trial code
- NCT07159789
- Record updated
- 9 November 2026
- Original description
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.Read full original descriptionShow less
Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
Inclusion: Signed informed consent; Age ≥ 18 years and less than 71 years; Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018); EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more; Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening; Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study; No change in disease modifying therapy for at least 3 months prior to screening; Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.
Exclusion: Any previous rTMS therapy for any indication; Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker; Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study; Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation; Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study; Pregnant or breastfeeding or intending to become pregnant during the study.